Inventiva S.A. (IVA) fair value analysis
Nasdaq · Updated 2026-10-19
IVA price how computed
Valuation status
Reports in EURIVA reports its results in EUR while its shares trade in US dollars.
Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for IVA until same-currency inputs are available. Price and market cap below are in US dollars; revenue and EPS are shown in EUR.
- Last price
- $3.46
- Sector
- Healthcare
- 12-month range
- $2.87–$7.15
- Market cap
- $817M
- From 52-week high
- -51.6%
- Shares outstanding
- 236M
- Rank in Healthcare by quality score
- #294 of 301
Last price is the 2026-10-01 month-start close, the freshest stored price; the chart runs through 2026-10-16.
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing treatments for diseases with high unmet medical needs, particularly in the areas of fibrosis, metabolism, and oncology. The company is based in France and operates as a Nasdaq-listed entity while conducting its research and development activities across Europe.
IVA currently ranks #294 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
Revenue and EPS are shown in EUR; the trailing P/E is omitted because an EPS in EUR against a US-dollar share price would mislead.
- Market cap
- $817M
- Revenue (TTM)
- EUR 4.53M
- Net margin
- -13243.1%
- EPS (TTM)
- EUR -1.92
- Gross margin
- -6930.4%
- Debt / equity
- 1.13
- Shares outstanding
- 236M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 36 · neutral
- 50-day average
- $4.05
- 200-day average
- $4.96
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Last 8 quarters vs consensus
- 2 beat, 6 missed
- Quarter by quarter
- 2026-03 ▲ beat (+100.0%)
2025-12 ▲ beat (+100.0%)
2025-09 ▼ miss (-3.4%)
2025-06 ▼ miss (-167.9%)
2025-03 ▼ miss (-365.1%)
2024-12 ▼ miss (-323.3%)
2024-09 ▼ miss (-35.7%)
2024-06 ▼ miss (-37.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 13 buy · 0 hold · 0 sell (13 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $15.2
- Target vs last price
- +339.3%
What our data shows for IVA
- Shares are trading in the lower third of their 12-month price range of $2.87–$7.15.
- The 14-day relative strength index sits at a neutral 36.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- IVA's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent IVA news
TickrTrends' derived news-sentiment signal for IVA is currently mixed, computed from recent coverage.
- Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript (seekingalpha.com, 2026-09-28)
- Inventiva S.A. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:IVA) 2026-09-28 (seekingalpha.com, 2026-09-28)
- Inventiva S.A. Reports Zero Revenues in H1 2026, Stock Ticker IVA (gurufocus.com, 2026-09-28)
What people are saying
Follow the IVA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — IVA's relative strength index moved from oversold territory into neutral zone this week, suggesting reduced selling pressure in the healthcare sector stock. The shift in RSI indicates a technical rebalancing, though the full valuation assessment remains pending further data collection.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — IVA's derived indicators shifted this week as its balance-sheet leverage band moved from low to moderate, while its revenue growth band declined to none. The Healthcare sector company now sits at an awaiting full valuation verdict as these fundamental changes are being assessed.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is IVA stock undervalued?
IVA reports its results in EUR while its shares trade in US dollars. Forward Fair Value needs earnings and price in the same currency, so TickrTrends publishes no fair-value verdict for IVA until same-currency inputs are available.
What is IVA's TickrTrends verdict?
IVA is currently marked 'Reports in EUR' - no verdict is published on inputs in two different currencies.
How does IVA compare to other Healthcare stocks?
IVA ranks #294 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is IVA overbought or oversold?
IVA's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does IVA usually beat earnings estimates?
Over its last 8 reported quarters IVA beat the consensus estimate 2 times and missed 6 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about IVA?
Of 13 analysts covering IVA, 13 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $15.2 (+339.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.